"We had another outstanding quarter with record revenue and positive Adjusted EBITDA...We are very excited with our VSDHOne release and onboarding clients to increase our growth pace" - Shane Madden, CEO of Hydreight
VANCOUVER, British Columbia and LAS VEGAS, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. ("Hydreight" or the "Company") ( TSXV: NURS )( OTCQB: HYDTF )( FSE: SO6 ), a fast-growing mobile clinical network and medical platform which enables flexible at-home medical services across 50 states in the United States, is pleased to announce its financial results for the third quarter ended September 30, 2024. All financial information is presented in Canadian dollars unless otherwise indicated.
Summary of Q3, 2024 Financial Highlights:
- Q3, 2024 GAAP revenue was $4.53 million an increase of 47% compared to Q3, 2023.
- Q3 2024 Topline1 record revenue of $6.12 million, an increase of 54% compared to Q3, 2023.
- Q3, 2024 Adjusted EBITDA1 was $48K compared to ($265K) in the comparative quarter.
- Q3, 2024 gross margin of $1.53 million compared to $1.27 million in Q3, 2023.
- The company has never raised or borrowed any additional capital since the original going public transaction in December 2022.
- The Company's cash position at September 30, 2024 is $1.21 million.
- The first 9 months of 2024 GAAP revenue was $12.00 million, an increase of 48% compared to the first 9 months of 2023.
- The first 9 months of 2024 Topline1 revenue was $16.58 million, an increase of 37% compared to the first 9 months of 2023.
- Hydreight Ranked Number 56 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500 and 9th in Deloitte's Technology Fast 50 Program Winners in Canada for 2024
- In partnership with two other companies, Hydreight launched VSDHOne, a telemedicine and e-Commerce solution, that helps companies launch a direct to consumer ("DTC") healthcare brand in all 50 States.
- Within the first 90 days, VSDHOne sold over 200 licenses across 50 States.
- Announced a normal course issuer bid on August 28, 2024, covering the period from Oct 4, 2024, to October 3, 2025.
- Signed a partnership with a company that works with US Government agencies for service and healthcare contracts.
Shane Madden, CEO of Hydreight commented, "We had an outstanding quarter with record revenue, Adjusted EBITDA1 and Adjusted Revenue1. We are very excited for our "VSDHONE" products expansion and cashflow from that in the upcoming year". Madden continues "Our balance sheet and P&L reflect a provision for US sales and use tax where we have taken the most conservative approach in recognizing a liability of uncertain timing and amount based on our internal and preliminary assessment of sales and use tax nexus under the most expansive taxability assumptions. Given the complexity of our corporate structure and State excise tax laws and regulations, we have engaged external tax professionals to prepare a detailed review of our corporate structure to determine the Company's liability for sales and use tax by revenue stream at the State-by-State level. We anticipate the liability to be settled at an amount materially less than the provision.
The Company believes the following Non-GAAP1 financial measures provide meaningful insight to aid in the understanding of the Company's performance and may assist in the evaluation of the Company's business relative to that of its peers:
| | | | | | |
| Three months ended September 30, | | Nine months ended September 30, | |
| | 2024 | | | 2023 | | % change | | | 2024 | | | 2023 | | % change
| |
| | | | | | |
Adjusted Revenue | $ | 6,122,257 | | $ | 3,974,626 | | 54% | | $ | 16,578,742 | | $ | 12,058,150 | | 37% | |
Deduct - deferred business partner contract revenue | | 50,160 | | | (1,784) | | | | (253,753) | | | 170,102 | | |
Deduct - business partner payouts on app service gross revenue | | 1,545,776 | | | 888,191 | | | | 4,828,357 | | | 3,751,745 | | |
GAAP Revenue | $ | 4,526,320 | | $ | 3,088,219 | | 47% | | $ | 12,004,138 | | $ | 8,136,303 | | 48% | |
| | | | | | |
Adjusted Gross Margin | $ | 1,583,331 | | $ | 1,267,431 | | 25% | | $ | 4,070,549 | | $ | 3,561,578 | | 14% | |
Deduct - deferred business partner contract revenue | | 50,160 | | | (1,784) | | | | (253,753) | | | 170,102 | | |
GAAP Gross Margin | $ | 1,533,171 | | $ | 1,269,215 | | 21% | | $ | 4,324,302 | | $ | 3,391,476 | | 28% | |
| | | | | | |
Adjusted EBITDA | $ | 47,690 | | $ | (265,221) | | 118% | | $ | 219,525 | | $ | (827,157) | | 127% | |
Deduct - amortization and depreciation | | 47,094 | | $ | 7,470 | | | | 118,283 | | | 39,728 | | |
Deduct - share-based payments | | 90,534 | | $ | 194,282 | | | | 526,988 | | | 194,282 | | |
GAAP Net Loss | $ | (89,938) | | $ | (466,973) | | 81% | | $ | (425,746) | | $ | (1,061,167) | | 60% | |
1 Refer to Use of Non-GAAP Financial Measures
The table below sets out a summary of certain financial results of the Company over the past eight quarters and is derived from the audited annual consolidated financial statements and unaudited quarterly consolidated financial statements of the Company.
| | Net Income (Loss) After Taxes | Comprehensive Income (Loss) | Basic and Diluted Income (Loss) Per Share |
Fiscal Quarter Ended | Revenue |
September 30, 2024 | 4,526,320 | (89,938) | | (53,119) | | (0) | |
June 30, 2024 | 4,100,212 | (27,087) | | (48,184) | | (0) | |
March 31, 2024 | 3,377,606 | (308,721) | | (370,559) | | (0) | |
December 31, 2023 | 3,373,193 | (898,561) | | (865,068) | | (0) | |
September 30, 2023 | 3,088,219 | (466,973) | | (548,954) | | (0) | |
June 30, 2023 | 2,699,668 | (471,890) | | (405,638) | | (0) | |
March 31, 2023 | 2,348,416 | (122,304) | | (121,502) | | (0) | |
December 31, 2022 | 1,695,134 | (5,060,755) | | (5,062,144) | | (1) | |
The Company has experienced dramatic user growth over the past two years as can be seen by the consistent revenue growth over the past eight quarters.
The Company continues to deliver on its mission of building one of the largest mobile clinical networks in the United States. Through its medical network, pharmacy network and proprietary technology platform that adheres to the complex healthcare legislation across 50 states, Hydreight has provided a fully integrated solution for healthcare providers to become independent contractors.
Hydreight remains focused on its strategic priorities of (1) Profitability (2) adding more product and service offerings for its customers, (3) introducing Hydreight story with more potential shareholders (4) driving white label partnerships and Nurses to the platform and (5) looking for strategic tuck in M&A opportunities to scale and grow the business quickly and efficiently. Hydreight will continue to invest into its technology to ensure continuous improvements, advancements and updates adhering to changes within the healthcare industry.
Please see SEDAR+ for the Company's condensed interim consolidated unaudited financial statements and MD&A for the three and six months ended September 30, 2024 and 2023 and for the Company's audited annual consolidated financial statements and MD&A for the year ended December 31, 2023 and 2022.
About VSDHOne - Direct to Consumer Platform
In a partnership with two other parties, Hydreight Technologies launched the VSDHOne (Read as VSDH-One)platform. VSDHOne simplifies the entry challenges for companies and medi-spa businesses to enter the online healthcare space compliantly. This platform will help all businesses to launch a direct-to-consumer healthcare brand in a matter of days in all 50 states. Compliant offerings include: GLP-1s (semaglutide, tirzepatide), peptides, personalized healthcare treatments, sermorelin, testosterone replacement therapy ("TRT"), hair loss, skincare, sexual health and more.
Hydreight invested in technology, legal and infrastructure to launch this platform. The VSDHOne platform offers a complete, end-to-end solution for businesses looking to launch direct-to-consumer healthcare brands. From compliance and telemedicine technology to nationwide doctor and pharmacy networks, VSDHOne provides all the tools needed for a seamless entry into the online healthcare space. The platform is designed to significantly reduce the time and costs associated with launching such services, making it possible for businesses to go live in days instead of months.
About Hydreight Technologies Inc.
Hydreight Technologies Inc. is building one of the largest mobile clinic networks in the United States. Its proprietary, fully integrated platform hosts a network of over 2500 nurses, over 100 doctors and a pharmacy network across 50 states. The platform includes a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking, and managing patient data, which enables licensed healthcare professionals to provide services directly to patients at home, office or hotel. Hydreight is bridging the gap between provider compliance and patient convenience, empowering nurses, med spa technicians, and other licensed healthcare professionals. The Hydreight platform allows healthcare professionals to deliver services independently, on their own terms, or to add mobile services to existing location-based operations. Hydreight has a 503B pharmacy network servicing all 50 states and is closely affiliated with a U.S. certified e-script and telemedicine provider network.
On behalf of the Board of Directors
Shane Madden
Director and Chief Executive Officer
Hydreight Technologies Inc.
Contact
Email: ir@hydreight.com; Telephone: (702) 970 8112
This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.
Use of Non-GAAP Financial Measures:
This release contains references to non-GAAP financial measures Adjusted Revenue (also referred to as Topline Revenue), Adjusted Gross Margin, and Adjusted EBITDA. The Company defines Adjusted Revenue as gross cash income before adjustment for the deferred portion of business partner contract revenue and gross receipts from Hydreight App service sales. The Company defines Adjusted Gross Margin as GAAP gross margin plus inventory impairment plus the deferred portion of business partner contract revenue. The Company defines Adjusted EBITDA as net income (loss) before interest, taxes, depreciation and amortization and before (i) transaction, restructuring, and integration costs and share-based payments expense, and (iii) gains/losses that are not reflective of ongoing operating performance. The Company believes that the measures provide information useful to its shareholders and investors in understanding the Company's operating cash flow growth, user growth, and cash generating potential for funding working capital requirements, service future interest and principal debt repayments and fund future growth initiatives. These non-GAAP measures may assist in the evaluation of the Company's business relative to that of its peers more accurately than GAAP financial measures alone. This data is furnished to provide additional information and does not have any standardized meaning prescribed by GAAP. Accordingly, it should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP and is not necessarily indicative of other metrics presented in accordance with GAAP.
Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.
Cautionary Note Regarding Forward-Looking Information
This press release contains statements which constitute "forward-looking information" within the meaning of applicable securities laws, including statements regarding the plans, path to profitability, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking information is often identified by the words "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" or similar expressions and includes information regarding expectations for the Company's growth and profitability in 2024.
Investors are cautioned that forward-looking information is not based on historical facts but instead reflects the Company's management's expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the ability to obtain requisite regulatory and other approvals with respect to the business operated by the Company and/or the potential impact of the listing of the Company's shares on the TSXV on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time as a result of being a publicly listed entity. This forward-looking information may be affected by risks and uncertainties in the business of the Company and market conditions.
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
1See Use of Non-GAAP Financial Measures
Hydreight首席执行官Shane Madden表示:“我们又迎来了一个出色的季度,收入创历史新高,调整后的息税折旧摊销前利润为正... 我们对VsDHone的发布和客户的加入以加快增长步伐感到非常兴奋。”
不列颠哥伦比亚省温哥华和拉斯维加斯 2024 年 11 月 26 日(环球新闻电讯)--Hydreight Technologies Inc.(以下简称 “Hydreight ”或 “公司”)(多伦多证券交易所股票代码:NURS)(美国场外柜台交易市场股票代码:HYDTF)(伦敦证券交易所股票代码:SO6)是一家快速发展的移动临床网络和医疗平台,可在美国 50 个州提供灵活的上门医疗服务。除非另有说明,所有财务信息均以加元列示。
2024 年第三季度财务亮点摘要:
2024 年第三季度的 GAAP 收入为 453 万美元,与 2023 年第三季度相比增长了 47%。
2024 年第三季度 Topline1 收入创纪录的 612 万美元,与 2023 年第三季度相比增长了 54%。
2024 年第三季度调整后的 EBITDA1 为4.8万美元,而同期为(26.5万美元)。
2024年第三季度的毛利率为153万美元,而2023年第三季度的毛利率为127万美元。
自2022年12月首次公开交易以来,该公司从未筹集或借入任何额外资金。
截至2024年9月30日,该公司的现金状况为121万美元。
2024年前9个月的GAAP收入为1,200万美元,与2023年前9个月相比增长了48%。
2024年Topline1的前9个月收入为1658万美元,与2023年前9个月相比增长了37%。
Hydreight在2024年德勤高科技高成长500强中排名北美增长最快的公司第56位,在德勤2024年加拿大高科技高成长50强项目获奖者中排名第9位
Hydreight与另外两家公司合作推出了VSDHone,这是一种远程医疗和电子商务解决方案,可帮助各公司在所有50个州推出直接面向消费者(“DTC”)的医疗保健品牌。
在最初的90天内,vsDhone在50个州售出了200多个许可证。
2024年8月28日宣布了普通课程发行人的出价,涵盖2024年10月4日至2025年10月3日期间。
与一家与美国政府机构合作签订服务和医疗保健合同的公司签署了合作伙伴关系。
Hydreight首席执行官谢恩·马登评论说:“我们的季度表现出色,收入创历史新高,调整后的 EBITDA1 和调整后的收入1。我们对来年我们的 “VSDHONE” 产品的扩展以及由此产生的现金流感到非常兴奋”。Madden继续说:“我们的资产负债表和损益反映了美国销售税和使用税的准备金,我们在最广泛的可纳税性假设下,根据对销售税和使用税关系的内部和初步评估,采取了最保守的方法来确认时间和金额不确定的负债。鉴于我们的公司结构和州消费税法律法规的复杂性,我们聘请了外部税务专业人员来准备对我们的公司结构进行详细审查,以确定公司在各州一级按收入来源分列的销售税和使用税负债。我们预计负债的结算金额将大大低于准备金。
公司认为,以下非GAAP1财务指标提供了有意义的见解,有助于理解公司的业绩,并可能有助于评估公司相对于同行的业务:
| | | | | | |
| 截至9月30日的三个月 | | 截至9月30日的九个月 | |
| | 2024 | | | 2023 | | 百分比变化 | | | 2024 | | | 2023 | | 百分比变化 | |
| | | | | | |
调整后的收入 | $ | 6,122,257 | | $ | 3,974,626 | | 54% | | $ | 16,578,742 | | $ | 12,058,150 | | 37% | |
扣除-延期业务合作伙伴合同收入 | | 50,160 | | | (1,784) | | | | (253,753) | | | 170,102 | | |
扣除-业务合作伙伴对应用服务总收入的支出 | | 1,545,776 | | | 888,191 | | | | 4,828,357 | | | 3,751,745 | | |
GAAP 收入 | $ | 4,526,320 | | $ | 3,088,219 | | 47% | | $ | 12,004,138 | | $ | 8,136,303 | | 48% | |
| | | | | | |
调整后的毛利率 | $ | 1,583,331 | | $ | 1,267,431 | | 25% | | $ | 4,070,549 | | $ | 3,561,578 | | 14% | |
扣除-延期业务合作伙伴合同收入 | | 50,160 | | | (1,784) | | | | (253,753) | | | 170,102 | | |
GAAP 毛利率 | $ | 1,533,171 | | $ | 1,269,215 | | 21% | | $ | 4,324,302 | | $ | 3,391,476 | | 28% | |
| | | | | | |
调整后 EBITDA | $ | 47,690 | | $ | (265,221) | | 118% | | $ | 219,525 | | $ | (827,157) | | 127% | |
扣除-摊销和折旧 | | 47,094 | | $ | 7,470 | | | | 118,283 | | | 39,728 | | |
扣除-基于股份的付款 | | 90,534 | | $ | 194,282 | | | | 526,988 | | | 194,282 | | |
GAAP 净亏损 | $ | (89,938) | | $ | (466,973) | | 81% | | $ | (425,746) | | $ | (1,061,167) | | 60% | |
1 参考非公认会计准则财务指标的使用
下表汇总了公司过去八个季度的某些财务业绩,摘要来自公司经审计的年度合并财务报表和未经审计的季度合并财务报表。
| | 净收益(亏损) 税后 | 全面 收入(亏损) | 基本版和稀释版 人均收入(亏损) 分享 |
财政季度已结束 | 收入 |
2024 年 9 月 30 日 | 4,526,320 | (89,938) | | (53,119) | | (0) | |
2024 年 6 月 30 日 | 4,100,212 | (27,087) | | (48,184) | | (0) | |
2024 年 3 月 31 日 | 3,377,606 | (308,721) | | (370,559) | | (0) | |
2023 年 12 月 31 日 | 3,373,193 | (898,561) | | (865,068) | | (0) | |
2023 年 9 月 30 日 | 3,088,219 | (466,973) | | (548,954) | | (0) | |
2023年6月30日 | 2,699,668 | (471,890) | | (405,638) | | (0) | |
2023 年 3 月 31 日 | 2,348,416 | (122,304) | | (121,502) | | (0) | |
2022年12月31日 | 1,695,134 | (5,060,755) | | (5,062,144) | | (1) | |
在过去的两年中,该公司的用户增长迅速,这可以从过去八个季度的持续收入增长中看出。
该公司继续履行其建设美国最大的移动临床网络之一的使命。通过其医疗网络、药房网络和遵守50个州复杂医疗法规的专有技术平台,Hydreight为医疗保健提供商成为独立承包商提供了完全集成的解决方案。
Hydreight仍然专注于其战略优先事项,即(1)盈利能力(2)为客户增加更多产品和服务,(3)向更多潜在股东介绍Hydreight的故事(4)推动白标合作伙伴关系和护士进入该平台,以及(5)在并购机会中寻找战略机会,以快速高效地扩展和发展业务。Hydreight将继续投资其技术,以确保根据医疗保健行业的变化进行持续改进、进步和更新。
请看看 SEDAR+ 关于公司截至2024年9月30日和2023年9月30日的三个月和六个月的简明中期合并未经审计的财务报表和MD&A,以及公司截至2023年和2022年12月31日止年度的经审计的年度合并财务报表和MD&A。
关于 vsDHone-直接面向消费者的平台
Hydreight Technologies与其他两方合作推出了vsDHone(读取为vSDH-One)平台。vsDhone简化了公司和医疗水疗企业合规进入在线医疗领域的进入挑战。该平台将帮助所有企业在短短几天内在所有50个州推出直接面向消费者的医疗保健品牌。合规产品包括:GLP-1(索玛鲁肽、替塞帕肽)、肽、个性化医疗保健治疗、舍莫瑞林、睾丸激素替代疗法(“TRT”)、脱发、护肤、性健康等。
Hydreight投资了技术、法律和基础设施,以启动该平台。vsDHone平台为希望推出直接面向消费者的医疗保健品牌的企业提供了完整的端到端解决方案。从合规和远程医疗技术到全国医生和药房网络,vsDhone提供了无缝进入在线医疗领域所需的所有工具。该平台旨在显著减少与推出此类服务相关的时间和成本,使企业有可能在几天而不是几个月内上线。
关于海德瑞特科技公司
Hydreight Technologies Inc. 正在建设美国最大的移动诊所网络之一。其专有的、完全集成的平台拥有一个由2500多名护士、100多名医生组成的网络和遍布50个州的药房网络。该平台包括一套内置、易于使用的完全集成的工具,用于会计、文档、销售、库存、预订和管理患者数据,使持牌医疗保健专业人员能够直接在家中、办公室或酒店为患者提供服务。Hydreight正在弥合提供者合规性与患者便利性之间的差距,为护士、医疗水疗技术人员和其他持牌医疗保健专业人员提供支持。Hydreight平台允许医疗保健专业人员按照自己的条件独立提供服务,或者在现有的基于位置的运营中添加移动服务。Hydreight拥有一个为所有50个州提供服务的5030药房网络,并与美国认证的电子脚本和远程医疗提供商网络密切相关。
代表董事会
Shane Madden
董事兼首席执行官
海德雷特科技公司
联系我们
电子邮件: ir@hydreight.com; 电话:(702) 970 8112
本新闻稿不构成在美国出售的证券要约。所发行的证券没有也不会根据经修订的1933年《美国证券法》进行注册,除非在美国注册或获得美国注册要求的适用豁免,否则不得在美国境内发行或出售此类证券。
非公认会计准则财务指标的使用:
本新闻稿提及非公认会计准则财务指标调整后收入(也称为收入总额)、调整后毛利率和调整后息税折旧摊销前利润。公司将调整后收入定义为调整业务合作伙伴合同收入的递延部分和Hydreight App服务销售总收入之前的总现金收入。公司将调整后的毛利率定义为GAAP毛利率加上库存减值加上业务合作伙伴合同收入的递延部分。公司将调整后的息税折旧摊销前利润定义为扣除利息、税项、折旧和摊销前的净收益(亏损),以及(i)交易、重组和整合成本以及基于股份的支付费用,以及(iii)未反映持续经营业绩的收益/亏损。该公司认为,这些措施为股东和投资者提供了有用的信息,帮助他们了解公司的运营现金流增长、用户增长以及为营运资本需求提供资金、偿还未来利息和本金债务以及为未来增长计划提供资金的现金创造潜力。与单独的GAAP财务指标相比,这些非公认会计准则指标可能有助于更准确地评估公司相对于同行的业务。提供这些数据是为了提供更多信息,不具有 GAAP 规定的任何标准化含义。因此,不应将其孤立地考虑,也不能作为根据公认会计原则制定的绩效衡量标准的替代品,也不一定表示根据公认会计原则提出的其他指标。
多伦多证券交易所及其监管服务提供商(该术语在多伦多证券交易所的政策中定义)均不对本新闻稿的充分性或准确性承担责任。本新闻稿不构成在美国出售证券的要约。所发行的证券没有也不会根据经修订的1933年《美国证券法》进行注册,如果没有美国注册或美国注册要求的适用豁免,则此类证券不得在美国境内发行或出售。
关于前瞻性信息的警示说明
本新闻稿包含构成适用证券法所指的 “前瞻性信息” 的声明,包括有关计划、盈利途径、意图、信念和公司对未来业务活动和经营业绩的当前预期的陈述。前瞻性信息通常用 “可能”、“将”、“可以”、“应该”、“打算”、“计划”、“预测”、“相信”、“估计”、“预期” 或类似表述来识别,包括有关公司2024年增长和盈利能力预期的信息。
提醒投资者,前瞻性信息不是基于历史事实,而是根据管理层在发表声明之日认为合理的观点、假设和估计,反映了公司管理层对未来业绩或事件的预期、估计或预测。尽管公司认为此类前瞻性信息中反映的预期是合理的,但此类信息涉及风险和不确定性,不应过度依赖此类信息,因为未知或不可预测的因素可能会对公司未来的业绩、业绩或成就产生重大不利影响。可能导致实际业绩与前瞻性信息中预测的业绩存在重大差异的关键因素包括:公司经营业务获得必要的监管和其他批准的能力和/或公司股票在多伦多证券交易所上市对包括与监管机构、员工、供应商、客户和竞争对手在内的关系的潜在影响;总体经济、商业和政治状况的变化,包括金融市场的变化;适用的法律;遵守广泛的政府规章;以及由于成为上市实体而分散管理时间。这些前瞻性信息可能会受到公司业务风险和不确定性以及市场状况的影响。
如果这些风险或不确定性中的一项或多项成为现实,或者前瞻性信息所依据的假设被证明不正确,则实际结果可能与本文描述的预期、计划、预期、相信、估计或预期的结果存在重大差异。尽管公司试图确定可能导致实际业绩存在重大差异的重要风险、不确定性和因素,但可能还有其他因素导致业绩与预期、估计或预期不符。除非适用法律另有要求,否则公司无意更新这些前瞻性信息,也不承担任何义务。
1参见非公认会计准则财务指标的使用